EGFR and non-small cell lung carcinoma: In a previous analysis of patients with T790M NSCLC and acquired resistance to osimertinib, patients with loss of detectable EGFR T790M had a shorter median time to treatment discontinuation compared with patients who retained EGFR T790M (6.1 months versus 15.2 months)14.